MeSH D019694 - chronic hepatitis b
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil | 2018-11-09 | |||
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil | 2017-06-08 | ||||
| Entecavir | Entecavir | 2014-08-26 | ||||
| Lamivudine | Lamivudine Teva | 2009-10-23 | ||||
| Tenofovir disoproxil | Tenofovir Disoproxil | 2015-03-18 | ||||
| Mylan | Tenofovir disoproxil, Lamivudine | Cimduo | 2018-02-28 | |||
| Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan | 2017-09-05 | ||||
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil | 2018-04-09 | ||||
| Emtricitabine, Tenofovir disoproxil | Emtricitabine/Tenofovir disoproxil Mylan | 2016-12-16 | ||||
| Entecavir | Entecavir Mylan | 2017-09-18 | ||||
| Tenofovir disoproxil, Efavirenz, Lamivudine | Symfi | 2018-03-22 | ||||
| Tenofovir disoproxil, Efavirenz, Lamivudine | Symfi Lo | 2018-02-05 | ||||
| Tenofovir disoproxil | Tenofovir Disoproxil | 2018-11-27 | ||||
| Tenofovir disoproxil | Tenofovir disoproxil Mylan | 2016-12-08 | ||||
| Johnson & Johnson | Tenofovir alafenamide, Cobicistat, Emtricitabine, Darunavir | Symtuza | 2022-02-02 | 2018-07-17 | ||
| GSK | Lamivudine | Zeffix | 1999-07-29 | |||
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | |||
| Cipla | Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil | 2019-06-03 | |||
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil | 2021-04-02 | ||||
| Entecavir | Entecavir | 2016-12-06 | ||||
| Tenofovir disoproxil | Tenofovir Disoproxil | 2018-01-26 | ||||
| Chartwell Pharmaceuticals | Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil | 2021-06-04 | |||
| Tenofovir disoproxil | Tenofovir Disoproxil | 2018-07-26 | ||||
| Entecavir | Entecavir | 2017-05-11 | ||||
| Tenofovir disoproxil, Lamivudine | Temixys | 2018-11-16 | ||||
| Novartis | Telbivudine | Sebivo | 2007-04-24 | |||
| Telbivudine | Tyzeka | 2023-09-11 | 2006-10-25 | |||
| Merck & Co | Doravirine, Tenofovir disoproxil, Lamivudine | Delstrigo | 2032-08-30 | 2018-08-30 | $249 M | Y2024 |
| Interferon alfa-2b | Intron A | 1986-06-04 | ||||
| Interferon alfa-2b | IntronA | 2000-03-09 | ||||
| Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
| Aurobindo Pharma | Emtricitabine, Tenofovir disoproxil, Efavirenz | Efavirenz, Emtricitabine, Tenofovir Disoproxil | 2018-09-04 | |||
| Tenofovir disoproxil, Efavirenz, Lamivudine | Efavirenz, Lamivudine Tenofovir Disoproxil | 2018-08-15 | ||||
| Emtricitabine, Tenofovir disoproxil | Emtricitabine Tenofovir Disoproxil | 2018-01-26 | ||||
| Entecavir | Entecavir | 2015-08-26 | ||||
| Tenofovir disoproxil, Lamivudine | Lamivudine Tenofovir Disoproxil | 2018-05-15 | ||||
| Tenofovir disoproxil | Tenofovir Disoproxil | 2018-01-26 |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
55%21/38
Phase 2
65%30/46
Phase 3
70%28/40
Approved: 12Overall Success rate: 25%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use